Ovarian Cystoma Cylioepithelial Malignant

Ovarian Cystoma Cylioepithelial Malignant: Understanding and Treatment

Introduction:
Ovarian cilioepitheliale malignisatum, also known as psammomatous ovarian carcinoma, malignant ovarian papillary carcinoma, malignant ovarian psammoma, serous cyst carcinoma, or serous cystadenocarcinoma, is a rare type of malignant ovarian tumor. In this article, we will review the main aspects of ovarian cilioepithelial cystoma malignant, including its characteristics, risk factors, diagnosis and treatment.

Characteristics:
Ovarian cilioepithelial malignant cystoma is a tumor that originates from the cells covering the surface of the ovary. This tumor usually has a papillary structure and may contain various types of cells, including columnar epithelial cells. Unlike the benignized form of cystoma, cilioepithelial malignant ovarian cystoma has the potential for invasive growth and spread to surrounding tissues.

Risk factors:
While the exact causes of the development of malignant cilioepithelial ovarian cystoma are unknown, certain risk factors may increase the likelihood of its occurrence. These risk factors include previous gynecological tumors, the presence of a hereditary syndrome of ovarian or breast cancer, and previous cancers of other organs.

Diagnostics:
Diagnosis of malignant cilioepithelial ovarian cystoma usually involves a comprehensive approach, including examination of the patient, physical examination, laboratory tests and instrumental methods. The clinical manifestations of ovarian cystoma can vary, and include symptoms such as lower abdominal pain, menstrual irregularities, and increased pressure on the bladder and rectum. Tests such as pelvic ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and biopsy may be ordered to confirm the diagnosis.

Treatment:
Treatment for ovarian cilioepithelial cystoma malignant usually involves surgery and additional therapy such as chemotherapy or radiation therapy. Surgery, such as removal of the tumor and surrounding affected tissue, is the main treatment. Depending on the stage and extent of the tumor, it may be necessary to remove one or both ovaries, the uterus, and surrounding lymph nodes. Chemotherapy may be used as an additional treatment to kill remaining cancer cells or to prevent recurrence. Radiation therapy may be used in some cases to shrink the tumor or control its growth.

Forecast and Forecasting:
The prognosis for patients with ovarian cilioepithelial malignant cystoma depends on many factors, including the stage of the disease, the extent of the tumor, the patient's age, and general health. Early detection and treatment are usually associated with a better prognosis. After surgical removal of the tumor, regular observation and monitoring of the patient may be recommended to detect recurrence or the development of other complications.

Conclusion:
Malignant cilioepithelial ovarian cystoma is a rare and aggressive form of ovarian tumor. Early detection, diagnosis and adequate treatment play an important role in the prognosis and survival of patients. Regular examinations with a gynecologist and following screening recommendations can help detect this disease in its early stages and increase the chances of successful treatment.

Cystomas are the most common group of benign ovarian tumors. Among them, mature and immature cysts are distinguished. Morphologically, they consist of epithelium, stroma and contain a secretion of mucin consistency inside [1].

There are several types of ovarian tumors that can lead to cystomas: cystadenomas, serous cysts and their combination - mixed tumors. Different types of ovarian tumors contain different mutations [2], although it remains unclear which of them determine individual phenotypic characteristics.

Malignant transformation of cystadenomas occurs quite rarely [3].

The difficulty of diagnosing malignant transformation of cystadencus is high and can be complicated by histological variability [4]. The ovarian tumor becomes malignant in more than half of the patients. Much depends on the size of the cyst - each five-millimeter cystadenofibroma is found in a patient with a chronic ovarian cyst in 25% of cases [4, 5].

Mixed cystadnazistomy and mixed type of ovarian pathology are more difficult to diagnose [6]. It is also necessary to consider the combined variant of transformation [7], when with solid ovarian tumors (for example, when acinar carcinoma is combined with cystadenoma), there is a risk of degenerative dysplasia [8], and there is a risk of developing an umbilical form of ovarian cancer with a low risk of recurrence [9] and predominantly local spread (trans- or retrograde lymphactosis) [12]. The development of myxoma (astrocytes) and fibrous cystadena (granulosis) usually occurs in one type of tumor and leads to a more aggressive course of the disease - cytoreductive surgery is indicated in the absence of response to chemotherapy [13, 14]. At the same time, the carcinomatous equivalent in other tumors is an accident or a malignancy syndrome of the desmoplastic type [6]: in such cases, borderline ovarian cancer without signs of visceral metastasis is diagnosed [15], immunotherapy is an additional treatment method [19, 44], and the response rate for treatment has a fairly high level [22].